Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients.
Bicanic, Tihana; Muzoora, Conrad; Brouwer, Annemarie E; Meintjes, Graeme; Longley, Nicky; Taseera, Kabanda; Rebe, Kevin; Loyse, Angela; Jarvis, Joseph; Bekker, Linda-Gail; Wood, Robin; Limmathurotsakul, Direk; Chierakul, Wirongrong; Stepniewska, Kasia; White, Nicholas J; Jaffar, Shabbar; Harrison, Thomas S.
Clin Infect Dis
; 49(5): 702-9, 2009 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-19613840
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.
Reproducibility of CSF quantitative culture methods for estimating rate of clearance in cryptococcal meningitis.
Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis.
Treatment of cryptococcal meningitis in resource limited settings.
Cryptococcal Meningitis Treatment Strategies Affected by the Explosive Cost of Flucytosine in the United States: A Cost-effectiveness Analysis.
Evaluation of trypan blue stain in the TC20 automated cell counter as a point-of-care for the enumeration of viable cryptococcal cells in cerebrospinal fluid.
The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis.
Adjunctive interferon-Î³ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial.
Relevance of intracranial hypertension control in the management of Cryptococcus neoformans meningitis related to AIDS.
A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis.